CB1 cannabinoid receptor-mediated changes of trabecular meshwork cellular properties

Molecular Vision

Volumn 12, Issue , 2006, Pages 290-297

  Kumarr, Akhilesh ^a   Song, Zhao Hui ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; ETHER DERIVATIVE; FIBRONECTIN; PAXILLIN; PHALLOIDIN; PROTEIN ANTIBODY; RIMONABANT;

ACTIN FILAMENT; ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CELL ADHESION; CELL ASSAY; CELL FUNCTION; CELL MIGRATION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLOGY; CYTOSKELETON; FLUORESCENCE ANALYSIS; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; STRESS FIBER; TRABECULAR MESHWORK; WOUND HEALING;

ANIMALS; CELL ADHESION; CELL MOVEMENT; CYTOSKELETON; FOCAL ADHESIONS; GLYCERIDES; MICROFILAMENTS; RECEPTOR, CANNABINOID, CB1; SWINE; TRABECULAR MESHWORK; WOUND HEALING;

EID: 33645570637     PISSN: 10900535     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74:129-80.
2. Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 2002; 66:101-21.
3. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346:561-4.
4. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365:61-5.
5. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258:1946-9.
6. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertweee RG, Griffine G, Bayewitchf M, Bargf J, Vogelf Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50:83-90.
7. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215:89-97.
8. Sugiura T, Kodaka T, Nakane S, Miyashita T, Kondo S, Suhara Y, Takayama H, Waku K, Seki C, Baba N, Ishima Y. Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds. J Biol Chem 1999; 274:2794-801.
9. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, Mechoulam R. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 2001; 98:3662-5.
10. Colasanti BK. Ocular hypotensive effect of marihuana cannabinoids: correlate of central action or separate phenomenon? J Ocul Pharmacol 1986; 2:295-304.
11. Jarvinen T, Pate DW, Laine K. Cannabinoids in the treatment of glaucoma. Pharmacol Ther 2002; 95:203-20.
12. Pate DW, Jarvinen K, Urtti A, Mahadevan V, Jarvinen T. Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits. Life Sci 1998; 63:2181-8.
13. Song ZH, Slowey CA. Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2. J Pharmacol Exp Ther 2000; 292:136-9.
14. Straiker AJ, Maguire G, Mackie K, Lindsey J. Localization of cannabinoid CB1 receptors in the human anterior eye and retina. Invest Ophthalmol Vis Sci 1999; 40:2442-8.
15. Stamer WD, Golightly SF, Hosohata Y, Ryan EP, Porter AC, Varga E, Noecker RJ, Felder CC, Yamamura HI. Cannabinoid CB(1) receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues. Eur J Pharmacol 2001; 431:277-86.
16. Tahir SK, Zimmerman AM. Influence of marihuana on cellular structures and biochemical activities. Pharmacol Biochem Behav 1991; 40:617-23.
17. Song ZH, Zhong M. CB1 cannabinoid receptor-mediated cell migration. J Pharmacol Exp Ther 2000; 294:204-9.
18. Sacerdote P, Massi P, Panerai AE, Parolaro D. In vivo and in vitro treatment with the synthetic cannabinoid CP55, 940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors. J Neuroimmunol 2000; 109:155-63.
19. Zhou D, Song ZH. CB1 cannabinoid receptor-mediated neurite remodeling in mouse neuroblastoma N1E-115 cells. J Neurosci Res 2001; 65:346-53.
20. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, Ferrarab P, Soubriea P, Brelierea JC, Le Fur GL. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350:240-4.
21. Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B, Portier M, Shire D, Breliere JC, Le Fur GL. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 1998; 284:644-50.
22. Polansky JR, Weinreb RN, Baxter JD, Alvarado J. Human trabecular cells. I. Establishment in tissue culture and growth characteristics. Invest Ophthalmol Vis Sci 1979; 18:1043-9.
23. Tripathi RC, Tripathi BJ. Human trabecular endothelium, corneal endothelium, keratocytes, and scleral fibroblasts in primary cell culture. A comparative study of growth characteristics, morphology, and phagocytic activity by light and scanning electron microscopy. Exp Eye Res 1982; 35:611-24.
24. Spessotto P, Giacomello E, Perris R. Fluorescence assays to study cell adhesion and migration in vitro. Methods Mol Biol 2000; 139:321-43.
25. Laine K, Jarvinen K, Mechoulam R, Breuer A, Jarvinen T. Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. Invest Ophthalmol Vis Sci 2002; 43:3216-22.
26. Juntunen J, Jarvinen T, Niemi R. In-vitro corneal permeation of cannabinoids and their water-soluble phosphate ester prodrugs. J Pharm Pharmacol 2005; 57:1153-7.
27. Song ZH, Njie Y. Effect of the endocannabinoid noladin ether on aqueous humor outflow facility. ARVO Annual Meeting; 2005 May 1-5; Fort Lauderdale (FL).
28. Hogg P, Calthorpe M, Ward S, Grierson I. Migration of cultured bovine trabecular meshwork cells to aqueous humor and constituents. Invest Ophthalmol Vis Sci 1995; 36:2449-60.
29. Hogg P, Calthorpe M, Batterbury M, Grierson I. Aqueous humor stimulates the migration of human trabecular meshwork cells in vitro. Invest Ophthalmol Vis Sci 2000; 41:1091-8.
30. Floyd BB, Cleveland PH, Worthen DM. Fibronectin in human trabecular drainage channels. Invest Ophthalmol Vis Sci 1985; 26:797-804.
31. Babizhayev MA, Brodskaya MW. Fibronectin detection in drainage outflow system of human eyes in ageing and progression of open-angle glaucoma. Mech Ageing Dev 1989; 47:145-57.
32. Steely HT, Browder SL, Julian MB, Miggans ST, Wilson KL, Clark AF. The effects of dexamethasone on fibronectin expression in cultured human trabecular meshwork cells. Invest Ophthalmol Vis Sci 1992; 33:2242-50.
33. Ryder MI, Weinreb RN, Alvarado J, Polansky J. The cytoskeleton of the cultured human trabecular cell. Characterization and drug responses. Invest Ophthalmol Vis Sci 1988; 29:251-60.
34. Francis BA, Alvarado J. The cellular basis of aqueous outflow regulation. Curr Opin Ophthalmol 1997; 8:19-27.